O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir

O6 Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir

Bibliographic Details
Main Authors:	Gilles Darcis, Sophie Bouchat, Anna Kula, Benoit Van Driessche, Nadège Delacourt, Caroline Vanhulle, Stéphane De Wit, Olivier Rohr, Christine Rouzioux, Carine Van Lint
Format:	Article
Language:	English
Published:	Elsevier 2016-09-01
Series:	Journal of Virus Eradication
Online Access:	http://www.sciencedirect.com/science/article/pii/S2055664020310852

Similar Items

Reactivation capacity by latency reversing agents ex vivo correlates with the size of the HIV-1 reservoir
by: Gilles Darcis, et al.
Published: (2016-05-01)

Sequential treatment with 5‐aza‐2′‐deoxycytidine and deacetylase inhibitors reactivates HIV‐1
by: Sophie Bouchat, et al.
Published: (2016-02-01)

Current Status of Latency Reversing Agents Facing the Heterogeneity of HIV-1 Cellular and Tissue Reservoirs
by: Amina Ait-Ammar, et al.
Published: (2020-01-01)

Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-04-01)

Corrigendum: Editorial: The relevance of molecular mechanisms in HIV-1 latency and reactivation from latency
by: Alexander O. Pasternak, et al.
Published: (2023-05-01)

OA2-1 Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1
by: S. Bouchat, et al.
Published: (2017-07-01)

Sequential treatment with 5-aza-2′deoxycitidine and deacetylase inhibitors reactivates HIV
by: C. Van Lint, et al.
Published: (2015-12-01)

Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1
by: C. Van Lint, et al.
Published: (2017-12-01)

O2 Identification of a new factor involved in DNA methylation-mediated repression of latent HIV-1
by: S. Bouchat, et al.
Published: (2017-09-01)

Transcription factor binding aites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity
by: Burny Arsène, et al.
Published: (2006-12-01)

Transcription factor binding sites in the pol gene intragenic regulatory region of HIV-1 are important for virus infectivity
by: Burny Arsène, et al.
Published: (2006-12-01)

DNA cytosine methylation in the Bovine Leukemia Virus promoter is associated with latency in a Lymphoma-derived B-cell line : potential involvement of direct inhibition of CREB/CREM/ATF binding
by: Van Lint Carine, et al.
Published: (2011-06-01)

The AP-1 binding sites located in the <it>pol </it>gene intragenic regulatory region of HIV-1 are important for virus infectivity
by: Van Lint Carine, et al.
Published: (2009-09-01)

Novel role of UHRF1 in the epigenetic repression of the latent HIV-1
by: Roxane Verdikt, et al.
Published: (2022-05-01)

8 Implication of the HIV-1 pol gene intragenic enhancer in myeloid-specific viral gene expression
by: R. Verdikt, et al.
Published: (2017-07-01)

CD32+CD4+ T Cells Are Highly Enriched for HIV DNA and Can Support Transcriptional Latency
by: Gilles Darcis, et al.
Published: (2020-02-01)

Microglial Cells: The Main HIV-1 Reservoir in the Brain
by: Clementine Wallet, et al.
Published: (2019-10-01)

The AP-1 binding sites located in the pol gene intragenic regulatory region of HIV-1 are important for viral replication.
by: Laurence Colin, et al.
Published: (2011-01-01)

The Quest for Cellular Markers of HIV Reservoirs: Any Color You Like
by: Gilles Darcis, et al.
Published: (2019-09-01)

5 Inhibition of HIV-1 gene transcription by KAP1: a new CTIP2 interactant
by: Amina Ait Ammar, et al.
Published: (2017-07-01)

CpG methylation controls reactivation of HIV from latency.
by: Jana Blazkova, et al.
Published: (2009-08-01)

Anti-latency agents to purge HIV reservoirs
by: Moreno Santiago
Published: (2012-05-01)

Synergistic activation of HIV-1 expression by deacetylase inhibitors and prostratin: implications for treatment of latent infection.
by: Sophie Reuse, et al.
Published: (2009-06-01)

HIV-1 Latency and Viral Reservoirs: Existing Reversal Approaches and Potential Technologies, Targets, and Pathways Involved in HIV Latency Studies
by: Sushant Khanal, et al.
Published: (2021-02-01)

Phorbol esters isolated from Croton megalobotrys reverse HIV latency ex vivo
by: I. Tietjen, et al.
Published: (2019-12-01)

Epigenetic Mechanisms of HIV-1 Persistence
by: Roxane Verdikt, et al.
Published: (2021-05-01)

Latency reversal plus natural killer cells diminish HIV reservoir in vivo
by: Jocelyn T. Kim, et al.
Published: (2022-01-01)

Potent latency reversal by Tat RNA-containing nanoparticle enables multi-omic analysis of the HIV-1 reservoir
by: Marion Pardons, et al.
Published: (2023-12-01)

Differences in HIV Markers between Infected Individuals Treated with Different ART Regimens: Implications for the Persistence of Viral Reservoirs
by: Gilles Darcis, et al.
Published: (2020-04-01)

The efficacy and tolerability of latency-reversing agents in reactivating the HIV-1 reservoir in clinical studies: a systematic review
by: Quinten Debrabander, et al.
Published: (2023-09-01)

SMAC mimetics are potent latency reversal agents with single agent and combination activity ex vivo
by: R.M. Dunham, et al.
Published: (2017-12-01)

Future approaches to clearing the latent human immunodeficiency virus reservoir: Beyond latency reversal
by: Alexander M.L. Hayes
Published: (2020-08-01)

PP 1.27 – 00147 Role of the pol gene enhancer in HIV-1 transcription and replication in myeloid infected cells
by: C. Van Lint, et al.
Published: (2022-12-01)

HIV interactions with monocytes and dendritic cells: viral latency and reservoirs
by: Wu Li, et al.
Published: (2009-06-01)

23 Understanding the effects of latency reversing agents on HIV RNA splicing: implications for latency reversal
by: T.M. Mota, et al.
Published: (2016-07-01)

Latency reversal agents affect differently the latent reservoir present in distinct CD4+ T subpopulations.
by: Judith Grau-Expósito, et al.
Published: (2019-08-01)

OP 1.7 – 00194 Potent latency reversal enables in-depth transcriptomic analysis of the translation-competent HIV-1 reservoir
by: M. Pardons, et al.
Published: (2022-12-01)

New Concepts in Therapeutic Manipulation of HIV-1 Transcription and Latency: Latency Reversal versus Latency Prevention
by: Catherine A. Lewis, et al.
Published: (2023-07-01)

Impact of latency‐reversing agents on human macrophage physiology
by: Laurent Hany, et al.
Published: (2023-01-01)

Combined noncanonical NF-κB agonism and targeted BET bromodomain inhibition reverse HIV latency ex vivo
by: Shane D. Falcinelli, et al.
Published: (2022-04-01)